Rituximab

Drug Profile

Rituximab

Alternative Names: IDEC-102; IDEC-C2B8; IDEC-C2B8-anti-CD20; MabThera; R 105; RG 105; Rituxan; Rituximab-EU; RO-452294

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Biogen Idec
  • Developer Biogen; Biogen Idec; Chugai Pharmaceutical; Genentech; Hoosier Cancer Research Network; Oregon Health & Science University; Roche; SCRI Development Innovations; Takeda Oncology; University of Texas M. D. Anderson Cancer Center; University of Tours; Zenyaku Kogyo
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma; Pemphigus vulgaris
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Follicular lymphoma; Lymphoproliferative disorders; Microscopic polyangiitis; Nephrotic syndrome; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Wegener's granulomatosis
  • Phase III Diffuse large B cell lymphoma; Mantle-cell lymphoma; Pemphigus vulgaris; Transplant rejection
  • Phase II/III Neuromyelitis optica
  • Phase II B cell lymphoma
  • No development reported Multiple sclerosis; Ocular inflammation; Primary biliary cirrhosis; Scleritis; Sjogren's syndrome; Ulcerative colitis
  • Discontinued Dermatomyositis; Graft-versus-host disease; Immune thrombocytopenic purpura; Lupus nephritis; Systemic lupus erythematosus

Most Recent Events

  • 01 May 2017 Phase-I/II clinical trials in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in Australia (IV) (NCT03135262)
  • 01 May 2017 Phase-I/II clinical trials in Follicular lymphoma (Combination therapy, Second-line therapy or greater) in Australia (IV) (NCT03135262)
  • 24 Mar 2017 Rituximab receives Breakthrough Therapy status for Pemphigus vulgaris in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top